Comparative Pharmacology
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus FEMOGEN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DROSPIRENONE ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM versus FEMOGEN.
DROSPIRENONE, ETHINYL ESTRADIOL AND LEVOMEFOLATE CALCIUM vs FEMOGEN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination of drospirenone (a progestin with antimineralocorticoid and antiandrogenic activity), ethinyl estradiol (an estrogen), and levomefolate calcium (a folate supplement). Prevents ovulation by suppressing gonadotropins; increases cervical mucus viscosity, inhibiting sperm penetration; levomefolate provides folate to reduce neural tube defect risk.
Femogen is a combination of estradiol (an estrogen) and norethindrone acetate (a progestin). Estrogens act by binding to nuclear estrogen receptors (ERα and ERβ) in target tissues, modulating gene expression and promoting proliferation of the endometrium. Norethindrone acetate suppresses gonadotropin secretion and inhibits endometrial proliferation, reducing the risk of endometrial hyperplasia associated with estrogen therapy.
One tablet orally once daily for 28 days (21 active tablets containing drospirenone 3 mg, ethinyl estradiol 0.02 mg, and levomefolate calcium 0.451 mg, followed by 7 placebo tablets containing levomefolate calcium 0.451 mg).
1 mg orally once daily for 21 days, followed by 7 days off; for HRT, 1 mg orally once daily continuously.
None Documented
None Documented
Drospirenone: ~30 hours (steady state achieved after 8 days). Ethinyl estradiol: ~13-17 hours (biphasic, terminal). Levomefolate calcium: ~4-6 hours (folate derivatives have longer retention).
Terminal half-life: 13.2 ± 2.3 hours; clinically, steady-state reached after 3-5 days.
Drospirenone: ~50% renal (as metabolites), ~40% fecal. Ethinyl estradiol: ~40% renal, ~60% fecal. Levomefolate calcium: ~70% renal (as folate metabolites), ~30% fecal.
Renal: 60-70% as glucuronide conjugates; Biliary/Fecal: 30-40% as metabolites; <1% unchanged.
Category D/X
Category C
Progestin + Estrogen
Estrogen